Abstract:Glycolic acid, the simplest α-hydroxy acid in structure, is extensively utilized in pharmaceuticals, chemicals, and other fields. However, the strains currently employed for the production of glycolic acid by fermentation typically possess plasmids or necessitate the addition of chemical inducers, which hampers large-scale industrial production. In order to construct a glycolic acid producing strain that does not require plasmids or chemical inducers. In this study, we utilized the wild-type strain Escherichia coli ATCC 8739 as the starting strain. Initially, we screened isocitrate lyase and glyoxylate reductase from different sources and constructed an engineered strain GA01 by genomic integration. Fermentation with this strain in a fermenter produced glycolic acid at a titer of 10.12 g/L. Following optimization of the copy number of pathway enzymes, the titer of glycolic acid was further increased to 15.25 g/L. Additionally, by blocking the branched metabolic pathways in the glycolic acid synthesis route and enhancing precursor supply, we effectively redirected carbon flow towards glycolic acid production, and fermentation with the optimized strain GA07-1 achieved the glycolic acid titer of 41.69 g/L. Finally, fermentation optimization was carried out with strain GA07-1 in a 5 L fermenter, achieving a glycolic acid titer of 50.62 g/L, a yield of 0.49 g/g, and productivity of 1.20 g/(h·L). These results realized the de novo fermentation of glycolic acid from glucose without antibiotics and chemical inducers.